Homocysteine and related genetic polymorphisms in Down’s syndrome IQ


Objective: Down’s syndrome (DS) is the most frequent genetic cause of Alzheimer-type dementia. Its metabolic phenotype involves an increased trans-sulphuration of homocysteine. The aim of the present study was to investigate the influence of homocysteinaemia (t-Hcys), folate, vitamin B₁₂, and related polymorphisms on intelligence quotient (IQ) in DS.

Methods: The IQ of 131 patients with trisomy 21 from a specialist centre in Sicily was determined and classified according to DSM-IV. The effects of age, folate, vitamin B₁₂, t-Hcys, and genetic polymorphisms on IQ were evaluated separately and in combination using regression analyses.

Results: IQ was significantly lower in DS patients with t-Hcys >7.5 μmol/l (median) and in those who were carriers of methylenetetrahydrofolate reductase (MTHFR) 677 T allele and of methylenetetrahydrofolate reductase 677 T and transcobalamin 776 G combined alleles (p = 0.0013, p = 0.0165, and p = 0.0074, respectively). The IQ correlated significantly with t-Hcys and folate in single and multiple regression analyses, independently of age. In addition, t-Hcys >9.6 μmol/l (upper quartile) was found to be associated with low IQ (<40, median of study group) with an odds ratio of 2.61 (p = 0.0203). The odds ratio was increased by threefold in carriers of MTHFR 677 T allele. The MTHFR 677 T allele/transcobalamin 776 G allele combination was associated with the risk of DS patients to have an IQ less that the median with an odds ratio of 2.68 (95% CI 1.26 to 5.70, p = 0.0104).

Conclusion: This study found evidence of an association between t-Hcys and MTHFR 677 T and transcobalamin 776 G alleles with IQ in patients with DS. The association may be related to a defective remethylation of homocysteine, affecting IQ.

In the present study, we investigated the relations between IQ, blood level of t-Hcys, related vitamins (folate and vitamin B₁₂), and genotypes of MTHFR, MTR, MTRR, transcobalamin (TCN), in 131 patients with DS.

PATIENTS AND METHODS

Patients

The 131 outpatients were recruited after obtaining the family’s and patient’s informed consent in a specialist centre receiving patients only from Sicily. The centre’s ethical committee approved the study.

Karyotyping showed full trisomy 21 in 100% of patients. The clinical characteristics taken into account when analysing the data were body mass index (BMI; only for patients older than 10 years), coeliac disease, cardiopathy, thyroid status, and epilepsy. None of the patients smoked, had renal failure (creatinine <15 mg/l in all cases), or took vitamin supplements or food fortified with vitamins. In all patients, the thyroid status was either normal or rendered euthyroid by replacement therapy. The IQ was tested with the Wechsler scales for adults and children, as described previously.²⁰ After testing, all subscale scores were transformed into age-scaled scores, the standard IQ calculated, and the mental retardation classified according to the DSM-IV, as specified by the American Society of Psychiatry (2000).²¹

Abbreviations: AD, Alzheimer’s disease; ApoE, Apolipoprotein E; BMI, body mass index; DS, Down’s syndrome; IQ, intelligence quotient; MTHFR, methylenetetrahydrofolate reductase; MTR, methionine synthase; MTRR, methionine synthase reductase; t-Hcys, homocysteine; TCN, transcobalamin

Downloaded from http://jnnp.bmj.com/ on June 21, 2017 - Published by group.bmj.com
Laboratory assays
Blood was collected in the fasting state. Plasma t-Hcys was assayed by fluorescence polarisation immunoassay (FPIA), and vitamin B12 and folate by microparticle enzyme immunoassay (MEIA) using the Abbott IMx automated benchtop analyser system (Abbott Diagnostic, Rome, Italy). DNA was isolated from a lymphocyte enriched fraction of whole blood with NUCLEON BACC3 for extraction of DNA was isolated from a lymphocyte enriched fraction of whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy). The procedures for detecting the whole blood with NUCLEON BACC3 for extraction of genomic DNA kit (Amersham Pharmacia Biotech, Milan, Italy).

Statistical methods
Categorical variables are reported as counts and percentages, and continuous variables as median, 25th and 75th centiles. For categorical and continuous variables, a continuity corrected χ² test and the Mann–Whitney U test were used, respectively. Spearman’s rank correlation coefficient was used to estimate the correlation among IQ, t-Hcys, age, folate and vitamin B12. The significance and odds ratios of continuous and categorical variables regarding mental retardation were determined by stepwise multiple regression and logistic regression analyses, respectively. A p value higher than 0.10 was set to exclude variables in the stepwise analyses and a final p value lower than 0.05 was considered to indicate residual statistical significance. Data were collected and analysed using the Statview 5 software for Windows (SAS Institute, Berkley, CA, USA) and the SPSS 10.0 software for Windows (SPSS, Paris, France).

RESULTS
The IQ of the 131 patients with DS ranged from 70 to 10, with median, 25th and 75th centiles of 40, 30, and 60, respectively. The plasma homocysteine levels were close to those observed in a control population (median, 25th and 75th centiles 7.5, 5.7, and 9.6 μmol/l, respectively). The plasma levels exceeded the 15 μmol/l limit of moderate hyperhomocysteinemia in nine patients, including five with a severe (IQ 35–25) and two with a profound (IQ<25) degree of mental retardation, according to the four degrees of the DSM-IV classification. We also found that patients who had t-Hcys levels >7.5 μmol/l had an IQ significantly lower than that of those who had a concentration below this median value (p = 0.0013, table 1). Reciprocally, t-Hcys was higher in DS patients with an IQ <40 (median of the study group), compared with those with less mental retardation (median and interquartiles: 8.19, 6.20, 10.50 and 6.80, 5.37, 8.70 μmol/l, respectively; p = 0.004).

Since t-Hcys was also related to age (table 2), we performed the same analysis in two age matched subgroups with IQ<40 (n = 29, mean (SD) age 19.7 (9.3) years) and >40 (n = 40, mean age 20.3 (8.8) years). The t-Hcys plasma level was still higher in the age matched group with IQ <40 (median and interquartiles: 8.4, 7.1, 9.3 and 6.9, 5.4, 8.8 μmol/l, respectively; p = 0.005). The IQ correlated significantly with t-Hcys and folate in log rank Spearman’s univariate analysis (table 2). This association was seen mainly in the patients who had the lowest IQ (p = 0.0013, table 1). Reciprocally, t-Hcys was higher in DS patients with an IQ <40 (median of the study group, compared with those with less mental retardation (median and interquartiles: 8.19, 6.20, 10.50 and 6.80, 5.37, 8.70 μmol/l, respectively; p = 0.004).

Table 2 Log rank Spearman’s correlation (rₛ) between intelligence quotient (IQ) and either age, homocysteine, or folate in 131 patients with Down’s syndrome (DS) and in two subgroups divided by IQ median (IQ = 40)

<table>
<thead>
<tr>
<th>Group</th>
<th>No of cases</th>
<th>Age</th>
<th>p value</th>
<th>Homocysteine</th>
<th>p value</th>
<th>Folate</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All DS</td>
<td>131</td>
<td>0.455</td>
<td>&lt;0.0001</td>
<td>-0.329</td>
<td>0.0002</td>
<td>0.110</td>
<td>0.2111</td>
</tr>
<tr>
<td>IQ≥40</td>
<td>69</td>
<td>0.546</td>
<td>&lt;0.0001</td>
<td>-0.167</td>
<td>0.1689</td>
<td>0.088</td>
<td>0.4705</td>
</tr>
<tr>
<td>IQ&lt;40</td>
<td>62</td>
<td>0.101</td>
<td>0.4285</td>
<td>-0.269</td>
<td>0.0355</td>
<td>0.328</td>
<td>0.0104</td>
</tr>
</tbody>
</table>
thyroid stimulating hormone (TSH), BMI, and age, the IQ remained associated only with t-Hcys (initial and residual p values 0.0112 and 0.0037, respectively) and folate (initial and residual p values 0.0967 and 0.0359, respectively). In a stepwise logistic regression analysis, we found an association between t-Hcys >9.6 μmol/l and IQ <40 (median) with an odds ratio of 2.61 (95% confidence interval (CI) 1.16 to 5.88; p = 0.0203), and IQ <30 (10th centile) with an odds ratio of 3.21 (95% CI 1.40 to 7.37, p = 0.0057).

There was no difference with regard to t-Hcys, folate, and vitamin B12 between patients with coeliac disease and the other patients (p = 0.363, 0.720, 0.351, respectively). We investigated the independent determinants of t-Hcys by multiple regression analysis—age and folate were but vitamin B12, transcobalamin, TSH, and BMI were not significant determinants (p = 0.0034 and p = 0.0232, respectively).

The distributions of MTHFR, MTR, MTRR, and TCN genotypes were in Hardy–Weinberg equilibrium. We evaluated the influence of these polymorphisms on the IQ, both alone and in combination with each other. The patient with DS bearing the MTHFR 677 T allele and the MTHFR 677 T/TCN 776 G allele combination had an IQ significantly lower than those carrying the corresponding wild genotypes (table 1). This effect was not age related, as the MTHFR 677 T allele and the MTHFR 677 T/TCN 776 G allele combination had no influence on the IQ of the carriers (p = 0.6299 and p = 0.7426, respectively). We also found a significant association of the MTHFR 677 T allele and TCN 776 G allele combination with the risk of DS patients to have a low IQ <median with an odds ratio of 2.68 (95% CI 1.26 to 5.70, p = 0.0104). There was no direct association of MTHFR 677 T allele with the risk of low IQ. However, this genotype increased the risk of low IQ associated with t-Hcys by about threefold with an odds ratio of 7.78 (95% CI 11.20 to 50.43, p = 0.0315).

**DISCUSSION**

Several clinical and experimental studies have hypothesised that patients with DS have disturbed one-carbon metabolism.6 19 25-27 t-Hcys, vitamin B12, and folate are metabolic and nutritional factors directly related to this metabolism. However, it remained unknown whether these factors and the associated genetic polymorphisms aggravate the age related mental retardation in DS.

The relatively low blood levels of t-Hcys in our patients can possibly be explained by an overexpression of the chromosomal 21 cystathionine-β-synthase enzyme, as has been observed by others.28 Despite these relatively low levels, we found a significant association between IQ and t-Hcys. Several hypotheses may explain this association. The relatively high t-Hcys levels in the subgroup of patients who had the lowest IQ could be an indirect consequence of mental retardation, since the latter may lead to reduced autonomy and subsequent deficient dietary intake. In fact, in our study, the influence of diet seemed to be limited to folate. We compared two age matched groups consisting of outpatients from an socioeconomic background. The BMI had no influence of the age of carriers (p = 0.6299 and p = 0.7426, respectively). We also found a significant association of the MTHFR 677 T allele and TCN 776 G allele combination with the risk of DS patients to have a low IQ <median with an odds ratio of 2.68 (95% CI 1.26 to 5.70, p = 0.0104). There was no direct association of MTHFR 677 T allele with the risk of low IQ. However, this genotype increased the risk of low IQ associated with t-Hcys by about threefold with an odds ratio of 7.78 (95% CI 11.20 to 50.43, p = 0.0315).

The relatively low blood levels of t-Hcys in our patients can possibly be explained by an overexpression of the chromosomal 21 cystathionine-β-synthase enzyme, as has been observed by others.28 Despite these relatively low levels, we found a significant association between IQ and t-Hcys. Several hypotheses may explain this association. The relatively high t-Hcys levels in the subgroup of patients who had the lowest IQ could be an indirect consequence of mental retardation, since the latter may lead to reduced autonomy and subsequent deficient dietary intake. In fact, in our study, the influence of diet seemed to be limited to folate. We compared two age matched groups consisting of outpatients from an socioeconomic background. The BMI had no influence of the age of carriers (p = 0.6299 and p = 0.7426, respectively). We also found a significant association of the MTHFR 677 T allele and TCN 776 G allele combination with the risk of DS patients to have a low IQ <median with an odds ratio of 2.68 (95% CI 1.26 to 5.70, p = 0.0104). There was no direct association of MTHFR 677 T allele with the risk of low IQ. However, this genotype increased the risk of low IQ associated with t-Hcys by about threefold with an odds ratio of 7.78 (95% CI 11.20 to 50.43, p = 0.0315).
been shown that homocysteine and folate deficiency increases the risk of neurodegenerative disorders.\textsuperscript{76} We also reported recently that MTR had an influence on the progression of AD, which may be enhanced by carriage of allele $e4$ of $\text{ApoE}$.\textsuperscript{76} Therefore, our previous results and the present data argue for investigating the potential interactions between homocysteine and $\beta$-amyloid fragment metabolism in the pathogenesis of DS dementia.

Authors’ affiliations

G Anello, P Bosco, C Barone, C Romano, IRCCS, Oasi Maria SS—Institute for Research on Mental Retardation and Brain Aging, Troina, EN, Italy

J-L Guéant, R-M Guéant-Rodríguez, P Gérard, Cellular and Molecular Pathology in Nutrition, EHE—INSERM 0014, Faculté de Médecine, Vandoosvre lès Nancy, France

A Romano, Department of Internal Medicine and Geriatrics, UCSC, CI Columbus, Rome, Italy

Competing interests: none declared

References


18 Wechsler D. Wechsler Adult Intelligence Scale Revised (WAIS-R). San Antonio, TX, USA: Psychological Corporation, 1981.


Homocysteine and related genetic polymorphisms in Down's syndrome IQ

J-L Guéant, G Anello, P Bosco, R-M Guéant-Rodríguez, A Romano, C Barone, P Gérard and C Romano

*J Neurol Neurosurg Psychiatry* 2005 76: 706-709
doi: 10.1136/jnnp.2004.039875

Updated information and services can be found at:
http://jnnp.bmj.com/content/76/5/706

These include:

**References**
This article cites 35 articles, 15 of which you can access for free at:
http://jnnp.bmj.com/content/76/5/706#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Dementia (1020)
- Drugs: CNS (not psychiatric) (1945)
- Memory disorders (psychiatry) (1390)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/